A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, 4‐Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants

Recently Approved and Upcoming Treatments for Narcolepsy

(2020) Michael J. Thorpy   CNS DRUGS

Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis

(2019) Katie Zomorodi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A randomized study of solriamfetol for excessive sleepiness in narcolepsy

(2019) Michael J. Thorpy et al.   ANNALS OF NEUROLOGY

Update on the Pharmacologic Management of Narcolepsy: Mechanisms of Action and Clinical Implications

(2019) Michael J. Thorpy et al.   SLEEP MEDICINE

Comparison of automated interval measurements by widely used algorithms in digital electrocardiographs

(2018) Paul Kligfield et al.   AMERICAN HEART JOURNAL

Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor

(2018) Michelle G. Baladi et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3): A Randomized Controlled Trial

(2018) Paula K. Schweitzer et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Solriamfetol for the Treatment of Excessive Sleepiness in OSA

(2018) Patrick J. Strollo et al.   CHEST

A Phase I, Randomized, Crossover, Open-Label Study of the Pharmacokinetics of Solriamfetol (JZP-110) in Healthy Adult Subjects With and Without Food

(2018) Katie Zomorodi et al.   CLINICAL THERAPEUTICS

A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor

(2018) Lawrence P Carter et al.   JOURNAL OF PSYCHOPHARMACOLOGY